One of the biggest challenges facing providers who want to deploy precision medicine at the point of care is the changes it requires for physician workflow. A new partnership between Edico Genome and InterSystems hopes to help with the movement of genomic data across clinical settings and electronic health records.
Deployed with InterSystems' HealthShare platform, Edico's DRAGEN Clinical Genomics Information System will help clinicians more easily order genomic tests – and will enable better analytics as such data is moved across the EHR.
Patients' genetic information can be shared bidirectionally, officials say, enabling harmonization of the massive amounts of genomic data generated by next-generation sequencing – ensuring that critical info is well integrated when physicians review the EHR and allowing clinicians to make more confident precision medicine decisions based clinical and phenotypic context.
[Also: Precision medicine: Huge promise, but high health IT-related hurdles, too]
"By ensuring connectivity between a patient’s genomic testing and their longitudinal health record, this partnership will give clinicians and patients alike better visibility into their complete health," said Paul Grabscheid, vice president of strategy for InterSystems, in a statement.
InterSystems' Health Connect interoperability technology aims to offer high-volume transaction support and continuous monitoring for clinical data. Edico Genome's CGIS is a comprehensive clinical genomics system designed to enable clinical labs to quickly and efficiently develop laboratory-developed tests.
[Also: HIMSS18 Precision Medicine Symposium to tackle clinical and business intelligence]
"Our goal is to make it as simple as possible for labs of all sizes to start using NGS in routine clinical care," said Pieter van Rooyen, CEO Edico Genome in a statement. "Through our partnership with InterSystems, we are able to integrate DRAGEN CGIS into the broader healthcare ecosystem day-to-day workflow and operations, enabling patient’s genetic and clinical data to be reviewed together and potentially leading to richer insights."
Twitter: @MikeMiliardHITN
Email the writer: mike.miliard@himssmedia.com